We provide you with 20 years of free, institutional-grade data for OGEN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OGEN. Explore the full financial landscape of OGEN stock.
| Reported Date | CIK | Ticker | Type |
|---|
Oragenics, Inc(NYSE MKT:OGEN) 
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product cand...
Website: http://www.oragenics.com
Founded: 1996
Full Time Employees: 7
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about OGEN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.